SG11201701645WA - Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia - Google Patents

Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Info

Publication number
SG11201701645WA
SG11201701645WA SG11201701645WA SG11201701645WA SG11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA
Authority
SG
Singapore
Prior art keywords
quinidine
dementia
agitation
treatment
pharmaceutical compositions
Prior art date
Application number
SG11201701645WA
Other languages
English (en)
Inventor
Joao Siffert
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of SG11201701645WA publication Critical patent/SG11201701645WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201701645WA 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia SG11201701645WA (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US201562217470P 2015-09-11 2015-09-11
US201562217142P 2015-09-11 2015-09-11
PCT/US2015/049934 WO2016040930A1 (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Publications (1)

Publication Number Publication Date
SG11201701645WA true SG11201701645WA (en) 2017-04-27

Family

ID=55459653

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701645WA SG11201701645WA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
SG10201901242PA SG10201901242PA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201901242PA SG10201901242PA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Country Status (14)

Country Link
US (3) US20190111047A1 (zh)
EP (4) EP4166141A1 (zh)
JP (4) JP2017531033A (zh)
KR (1) KR20170052684A (zh)
CN (3) CN107072990A (zh)
AU (3) AU2015314710A1 (zh)
CA (1) CA2960031A1 (zh)
IL (2) IL250786A0 (zh)
MX (3) MX2017003066A (zh)
PH (1) PH12017500444A1 (zh)
RU (2) RU2017112747A (zh)
SG (2) SG11201701645WA (zh)
TW (3) TW202231278A (zh)
WO (1) WO2016040930A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180243289A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
CA2994153A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
KR20230017361A (ko) * 2016-07-04 2023-02-03 아바니르 파마슈티컬스, 인코포레이티드 중수소화 덱스트로메토르판의 합성 방법
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CA3100897A1 (en) * 2018-05-18 2019-11-21 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
CR20210368A (es) * 2019-01-07 2021-12-10 Antecip Bioventures Ii Llc Combinación de dextrometorfano y bupropión para el tratamiento de depresión
SG11202110150YA (en) * 2019-03-18 2021-10-28 Avanir Pharmaceuticals Inc Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
KR20230016636A (ko) * 2020-04-27 2023-02-02 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법
WO2022228363A1 (zh) * 2021-04-27 2022-11-03 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
CA3236017A1 (en) * 2021-10-27 2023-05-04 Sanjay Dube Methods of treating agitation associated with alzheimer's disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
TW264473B (zh) * 1993-01-06 1995-12-01 Hoffmann La Roche
EP1634597A1 (en) * 1994-09-22 2006-03-15 Richard Alan Smith Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA2641392A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
US20070224128A1 (en) * 2006-03-07 2007-09-27 Donn Michael Dennis Drug adherence monitoring system
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
DK2345653T3 (da) * 2007-05-01 2013-04-08 Concert Pharmaceuticals Inc Morphinanforbindelser
ES2402088T3 (es) * 2008-09-19 2013-04-26 Concert Pharmaceuticals Inc. Compuestos de morfinano
EP3090760A1 (en) * 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
CA2743902C (en) * 2008-11-14 2016-09-20 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
NZ758431A (en) * 2013-11-05 2021-07-30 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Also Published As

Publication number Publication date
CA2960031A1 (en) 2016-03-17
PH12017500444A1 (en) 2017-07-31
JP7360409B2 (ja) 2023-10-12
EP3193872A1 (en) 2017-07-26
MX2021010696A (es) 2021-10-01
EP3932907A3 (en) 2022-03-30
CN110664801A (zh) 2020-01-10
RU2017112747A3 (zh) 2019-04-29
JP2023105265A (ja) 2023-07-28
IL250786A0 (en) 2017-04-30
EP4166141A1 (en) 2023-04-19
MX2017003066A (es) 2017-09-12
EP3932907A2 (en) 2022-01-05
JP2020019818A (ja) 2020-02-06
EP3193872A4 (en) 2018-02-28
AU2015314710A1 (en) 2017-04-20
TW202231278A (zh) 2022-08-16
EP3708168A3 (en) 2020-12-09
JP2017531033A (ja) 2017-10-19
EP3708168A2 (en) 2020-09-16
US20240082237A1 (en) 2024-03-14
SG10201901242PA (en) 2019-03-28
IL274742A (en) 2020-07-30
TW201613591A (en) 2016-04-16
RU2017112747A (ru) 2018-10-15
AU2022283671A1 (en) 2023-02-02
CN107072990A (zh) 2017-08-18
MX2022008181A (es) 2022-08-10
US20200289499A1 (en) 2020-09-17
AU2020289733A1 (en) 2021-01-21
RU2020116666A (ru) 2020-07-31
TW202106301A (zh) 2021-02-16
KR20170052684A (ko) 2017-05-12
CN117427077A (zh) 2024-01-23
US20190111047A1 (en) 2019-04-18
WO2016040930A1 (en) 2016-03-17
JP2021080300A (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
IL274742A (en) Pharmaceutical preparations containing the compound dextromethorphan and quinidine for the treatment of restlessness in dementia
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
HK1254054A1 (zh) 富馬酸二甲酯顆粒和其藥物組合物
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
HK1245113A1 (zh) 藥物組合物及其用途
IL251345B (en) Preparations for use in the treatment of peri-implantitis
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
FI3842436T3 (fi) Imidatsopyrimidiini- tai imidatsotriatsiinijohdannaisia käsittäviä farmaseuttisia koostumuksia käytettäväksi skitsofrenian hoidossa
SG11201609701UA (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
GB201616880D0 (en) Compound for use in medicine
SG11201704282UA (en) Compositions and methods for the treatment of multiple sclerosis